Heart failure management. Interview with Karl Swedberg.
Swedberg
Karl
K
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000628:therapy; D001552:Benzazepines / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002303:Cardiac Output, Low / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D002908:Chronic Disease; D017147:Defibrillators, Implantable; D006801:Humans; D000077550:Ivabradine; D017410:Practice Guidelines as Topic; D013777:Tetrazoles / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077550:Ivabradine; C081643:candesartan